Bantam Pharmaceutical is developing small molecule cancer therapeutics for hematological malignancies and select solid tumors. FDA recently cleared our Phase 1 protocol for a first in humans study that we intend to initiate in 2023. We are seeking biopharma partners or investors to join our current investors in bringing this important novel treatment option to the clinic.